State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 901–1,000 of 1,003
Overview of the Potency of Moxifloxacin Ophthalmic Solution 0.5% (VIGAMOX®)
Schlech, B. A., & Alfonso, E. C. (2005) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2005.05.002 · Cited by 39
Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model
Bowker, K. E., Noel, A. R., & MacGowan, A. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00922-07 · Cited by 39
Onyeji, C. O., Bui, K. Q., Owens, R. C., Nicolau, D. P., Quintiliani, R., & Nightingale, C. H. (1999) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(98)00087-9 · Cited by 39
“Literature reports suggest that the therapeutic activities of quinolones in experimental infections are related to their pharmacokinetic behavior [7,22,24,25].”
BackgroundCost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance
Kuti, J. L., Capitano, B., & Nicolau, D. P. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220080-00002 · Cited by 39
Boonpeng, A., Jaruratanasirikul, S., Jullangkoon, M., Samaeng, M., Wattanavijitkul, T., Bhurayanontachai, R., & Pattharachayakul, S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00845-22 · Cited by 38
Chaira, T., Subramani, C., & Barman, T. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041212 · Cited by 38
Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis
Maranchick, N. F., & Peloquin, C. A. (2024) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2024.100444 · Cited by 38
“…the peak drug concentrations relative to minimum inhibitory concentration (C max /MIC), the percentage of time within a dosing interval that concentrations exceed MIC (%T > MIC), and the area under the concentration time curve to MIC (AUC 0-τ /MIC), most commonly over 24 h (AUC 0-24 ) [16].”
BackgroundLees, P., Potter, T., Pelligand, L., & Toutain, P. (2017) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12439 · Cited by 38
“The scientific literature has, almost invariably, classified amoxicillin together with other penicillins as time dependent in killing actions (Craig, 1998; Frimodt-Moller, 2002; McNab & Bui, 2002; Martinez & Silley, 2010).”
BackgroundMethodAbdul-Aziz, M. H., Portunato, F., & Roberts, J. A. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000681 · Cited by 38
“Beta-lactam antibiotics display ‘time-dependent’ bactericidal activity, which is optimal when the duration of time (T) that the free drug concentration remains above the minimum inhibitory concentration (MIC) during a dosing interval (fT>MIC) is at least 40–70% [2].”
BackgroundInfluentialChua, N. G. S., Loo, L., Hee, D. K.-H., Lim, T.-P., Ng, T. M., Hoo, G. S. R., Soong, J. L., Ong, J. C. L., Tang, S. S. L., Zhou, Y. P., et al. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.12.013 · Cited by 38
Biological activity and fatty acid composition of Caesar's mushroom
Doğan, H. H., & Akbaş, G. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.768272 · Cited by 38
Estrada, D. V., Mora, J. G., & Sumano, H. (2007) · Research in Veterinary Science · doi:10.1016/j.rvsc.2007.07.003 · Cited by 38
Model System to Define Pharmacokinetic Requirements for Antimalarial Drug Efficacy
Bakshi, R. P., Nenortas, E., Tripathi, A. K., Sullivan, D. J., & Shapiro, T. A. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006684 · Cited by 38
Sprandel, K. A., Schriever, C. A., Pendland, S. L., Quinn, J. P., Gotfried, M. H., Hackett, S., Graham, M. B., Danziger, L. H., & Rodvold, K. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4597-4605.2004 · Cited by 38
“Recent advances in the understanding of antimicrobial pharmacodynamics have provided us the opportunity to optimize dosing regimens for old and new agents (7, 9).”
BackgroundEvaluating Outcomes of Alternative Dosing Strategies for Cefepime: A Qualitative Systematic Review
Burgess, S. V., Mabasa, V. H., Chow, I., & Ensom, M. H. H. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014564179 · Cited by 38
“Achieving at least 30% to 40% and 60% to 70%fT>MIC are associated with bacteriostatic and bactericidal activity, respectively.(8) Data supporting this PK-PD target have been derived mainly from animal studies and correlation with clinical effectiveness in humans is less clear.”
BackgroundResultPoor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis
Shenje, J., Adimora-Nweke, F. I., Ross, I. L., Ntsekhe, M., Wiesner, L., Deffur, A., McIlleron, H., Pasipanodya, J. G., Gumbo, T., & Mayosi, B. M. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.09.025 · Cited by 38
“The reasons for therapy failure are unclear, but could include high bacterial burden, concurrent immunodeficiency, or treatment factors that could be summarized as antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) (Gumbo et al., 2015a; Craig, 1998).”
BackgroundMethodInfluentialLim, S. M. S., Sime, F. B., & Roberts, J. A. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.02.016 · Cited by 38
Joly‐Guillou, M., Wolff, M., Farinotti, R., Bryskier, A., & Carbon, C. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.827 · Cited by 38
“In vitro and animal studies have shown that fluoroquinolones exhibit a concentration-dependent antibacterial activity.(5) In our murine model, the pharmacodynamic properties of levofloxacin were studied using two A.”
BackgroundNew Strategies for Antibacterial Drug Design: Targeting Non-Multiplying Latent Bacteria
Coates, A. R. M., & Hu, Y. (2006) · Drugs in R&D · doi:10.2165/00126839-200607030-00001 · Cited by 38
Making the most of surveillance studies: summary of the OPTAMA Program
Kuti, J. L., & Nicolau, D. P. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.10.004 · Cited by 38
“Drug exposure, governed by the pharmacokinetic profile of an antibiotic, relative to the MIC, also needs to be considered and is a strong predictor of microbiological outcome as evident in numerous animal and human pharmacodynamic studies (Craig, 1998).”
BackgroundDevelopment potential of rifalazil and other benzoxazinorifamycins
Rothstein, D. M., Shalish, C., Murphy, C. K., Sternlicht, A. L., & Campbell, L. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.6.603 · Cited by 38
“aureus in the septicaemia model [150]; however, NCEs failed to show efficacy in the mouse thigh model of infection [151], a more realistic and more predictive model of serious Gram-positive infections [152].”
BackgroundBurgess, D. S., & Frei, C. R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki335 · Cited by 38
Use of pharmacodynamic principles to inform β‐lactam dosing: “S” does not always mean success
Lodise, T. P., & Butterfield, J. M. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.869 · Cited by 37
“It is important to note that it is the free (or unbound) fraction of drug that determines its ability to penetrate tissues and exert its microbiological effect.(3,4,22) This was demonstrated as early as the 1940s with penicillin.”
BackgroundCutaneous Model of Invasive Aspergillosis
Ben-Ami, R., Lewis, R. E., Leventakos, K., Latgé, J.-P., & Kontoyiannis, D. P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01504-09 · Cited by 35
“Cutaneous infection models have been used extensively to study the pathogenesis and in vivo response to antibacterial agents of Gram-positive bacteria (8, 10).”
BackgroundBakterielle Sepsis: Diagnostik und kalkulierte Antibiotikatherapie
Richter, D., Heininger, A., Brenner, T., Hochreiter, M., Bernhard, M., Briegel, J., Dubler, S., Grabein, B., Hecker, A., Krüger, W. A., et al. (2017) · Der Anaesthesist · doi:10.1007/s00101-017-0363-8 · Cited by 37
Tamatsukuri, T., Ohbayashi, M., Kohyama, N., Kobayashi, Y., Yamamoto, T., Fukuda, K., Nakamura, S., Miyake, Y., Dohi, K., & Kogo, M. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.07.007 · Cited by 37
Rodríguez-Núñez, O., Periañez-Párraga, L., Oliver, A., Munita, J. M., Bote, A. C., Gasch, O., Nuvials, X., Dinh, A., Shaw, R. H., Lomas, J. M., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz416 · Cited by 37
“The majority of animal models have demonstrated that fT > MIC values of ≥60%–70% for cephalosporins, ≥50% for penicillins, and ≥40% for carbapenems provide maximal bactericidal effect [27].”
BackgroundAl‐Shaer, M. H., Neely, M. N., Liu, J., Cherabuddi, K., Venugopalan, V., Rhodes, N. J., Klinker, K. P., Scheetz, M. H., & Peloquin, C. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00745-20 · Cited by 37
“Preclinical studies on cephalosporins suggested that these antimicrobials have a static effect at 30% to 40% fT MIC and maximal killing effect at 60% to 70% (23, 24), while a trough-to-MIC ratio of 3.”
BackgroundMoniz, P., Coelho, L., & Póvoa, P. M. S. R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01558-w · Cited by 38
“On the contrary, for aminoglycosides and fluoroquinolones, the main pharmacokinetic/pharmacodynamic patterns related to AMT efficiency are peak/MIC and/or AUC/MIC ratios, reflecting concentration maximization [76].”
BackgroundZobell, J. T., Young, D. C., Waters, C. D., Ampofo, K., Stockmann, C. R., Sherwin, C. M. T., & Spigarelli, M. G. (2013) · Pediatric Pulmonology · doi:10.1002/ppul.22757 · Cited by 37
“For example, the effect of the beta-lactams is dependent on achieving antibiotic levels above the MIC for an extended duration of time.(63) In contrast, aminoglycoside activity is dependent upon achieving high peak plasma concentrations, such that higher peak concentrations achieve faster rates of bacterial killing.”
BackgroundWang, H., Zhang, B., Ni, Y., Kuti, J. L., Chen, B., Chen, M., & Nicolau, D. P. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.06.005 · Cited by 37
“[3] Craig WA.”
A proposal of clinical breakpoints for amoxicillin applicable to porcine respiratory tract pathogens
Schwarz, Š., Böttner, A., Gossens, L., Hafez, H. M., Hartmann, K., Kaske, M., Kehrenberg, C., Kietzmann, M., Klarmann, D., Klein, G., et al. (2007) · Veterinary Microbiology · doi:10.1016/j.vetmic.2007.06.023 · Cited by 37
“This means that its concentration in the infected tissue must be 336 above the MIC of the causative bacterial pathogen (Craig, 1998; Kietzmann et al., 337 2004).”
BackgroundLevofloxacin Pharmacokinetics and Pharmacodynamics in Patients with Severe Burn Injury
Kiser, T. H., Hoody, D. W., Obritsch, M. D., Wegzyn, C. O., Bauling, P. C., & Fish, D. N. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01466-05 · Cited by 37
“It has been suggested that the Cmax/MIC ratio may actually be the most suitable pharmacodynamic target for these concentration-dependent drugs and that achieving favorable AUC0–24/MIC ratios becomes more important when appropriate Cmax/MIC targets cannot be reached (8, 10, 25, 36).”
BackgroundChiou, C. C. (2005) · Clinical Infectious Diseases · doi:10.1086/499596 · Cited by 37
“the time (T) greater than MIC is the relevant PK/PD parameter [36, 37].”
BackgroundOvercoming barriers to optimal drug dosing during ECMO in critically ill adult patients
Cheng, V., Abdul-Aziz, M. H., Roberts, J. A., & Shekar, K. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1563596 · Cited by 37
Marchetti, O., Majcherczyk, P. A., Glauser, M. P., Billé, J., Moreillon, P., & Sanglard, D. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.696-700.2001 · Cited by 37
“Finally, pharmacokinetic studies are important in experimental treatment models (4).”
BackgroundPharmacokinetic and pharmacodynamic profile of ceftobiprole
Lodise, T. P., Patel, N., Renaud-Mutart, A. C., Gorodecky, E., Fritsche, T. R., & Jones, R. N. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.02.013 · Cited by 37
“Likewise, near maximal organism kill could be achieved at 50% fT N MIC for staphylococci and 60% fT N MIC for Gram-negative bacilli (Andes and Craig, 2000; Craig, 1998).”
BackgroundAntimicrobial use and resistance
Rubin, M. A., & Samore, M. H. (2002) · Current Infectious Disease Reports · doi:10.1007/s11908-002-0034-y · Cited by 37
Predicting drug resistance evolution: insights from antimicrobial peptides and antibioticsPreprint
Yu, G., Baeder, D. Y., Regoes, R. R., & Rolff, J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/138107 · Cited by 37
Crandon, J. L., Luyt, C. E., Aubry, A., Chastre, J. E., & Nicolau, D. P. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw200 · Cited by 36
Rizk, N., Kanafani, Z. A., Tabaja, H., & Kanj, S. S. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1348894 · Cited by 36
“This allows for a therapeutic advantage for organisms with MICs above the susceptible breakpoint [18], especially as resistance becomes increasingly important in determining clinical outcomes [34].”
BackgroundPopulation Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants
Shi, Z.-R., Chen, X., Tian, L., Wang, Y., Zhang, G.-Y., Dong, L., Jirasomprasert, T., Jacqz-Aigrain, É., & Zhao, W. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02486-17 · Cited by 36
“In order to obtain the maximal bactericidal activity of cephalosporin, a probability of target attainment of 70% was required for a 70% dosing interval (29, 30).”
Tanner, L., Denti, P., Wiesner, L., & Warner, D. F. (2018) · IUBMB Life · doi:10.1002/iub.1866 · Cited by 36
Gumbo, T., & Alffenaar, J. C. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy608 · Cited by 36
“The HFS-TB models and design described in the current article are not new; they go back 16 years in the tuberculosis field and are based on general PK/PD work with other bacteria [3, 5–7].”
BackgroundToutain, P., Sidhu, P. K., Lees, P., Rassouli, A., & Pelligand, L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01310 · Cited by 36
“4 rodent infection model that, for several decades (Craig, 1998) (Andes and Craig, 2002), was 121 used to select the best PK/PD index.”
MethodPhilpott, C. D., Droege, C. A., Droege, M. E., Healy, D. P., Courter, J. D., Ernst, N. E., Harger, N. J., Foertsch, M. J., Winter, J., Carter, K. E., et al. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2332 · Cited by 36
Papich, M. G. (2020) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12921 · Cited by 36
Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond
Rao, G. G., & Landersdorfer, C. B. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106368 · Cited by 36
Lees, P., Pelligand, L., Illambas, J., Potter, T., Lacroix, M. Z., Rycroft, A. N., & Toutain, P. (2015) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12207 · Cited by 36
“The scientific literature has, almost invariably, classified amoxicillin together with other penicillins as time dependent in killing actions (Craig, 1998; Frimodt-Moller, 2002; McNab & Bui, 2002; Martinez & Silley, 2010).”
BackgroundYoung, S. W., Roberts, T. L., Johnson, S., Dalton, J. P., Coleman, B., & Wiles, S. (2015) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-015-4464-x · Cited by 36
“Initiation of bacterial killing is known to occur earlier with increasing cefazolin concentrations [10], a factor likely to be more important in prophylaxis where preventing initial bacterial adherence and subsequent biofilm formation is required.”
BackgroundThe Pharmacodynamics of Antimicrobial Agents
Martinez, M. N., Toutain, P., & Turnidge, J. D. (2013) · Wiley eBooks · doi:10.1002/9781118675014.ch5 · Cited by 36
Rey, J. F., Laffont, C. M., Croubels, S., Backer, P. D., Zemirline, C., Bousquet, E., Guyonnet, J., Ferran, A. A., Bousquet‐mélou, A., & Toutain, P. (2014) · American Journal of Veterinary Research · doi:10.2460/ajvr.75.2.124 · Cited by 36
“15 From the 4 sources of data, 10 formulations were grouped by route of administration (IV [formulations 1 to 3], PO [formulations 4 to 8], or IM [formulations 9 and 10]).”
BackgroundAdnan, S., Paterson, D. L., Lipman, J., Kumar, S., Li, J., Rudd, M., & Roberts, J. A. (2012) · Surgical Infections · doi:10.1089/sur.2011.046 · Cited by 36
“Antibiotics can be divided into three major classes on the basis of their bacterial-killing properties [34].”
Bhavnani, S. M., & Andes, D. R. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.5.717.63583 · Cited by 36
Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers
Sowinski, K. M., Mueller, B. A., Grabe, D. W., Manley, H. J., Frye, R. F., Bailie, G. R., & Marx, M. A. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80126-8 · Cited by 36
What In Vitro Models of Infection Can and Cannot Do
White, R. L. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.18.292s.33906 · Cited by 36
Pichichero, M. E., & Reed, M. D. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911040-00003 · Cited by 36
Shea, K. M., Cheatham, S. C., Wack, M. F., Smith, D. W., Sowinski, K. M., & Kays, M. B. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.07.004 · Cited by 36
“concentration (fT>MIC) of the organism is the pharmacodynamic parameter that predicts clinical and bacteriological outcomes for this drug class [1–3].”
BackgroundInfluentialNicasio, A. M., Bulitta, J. B., Lodise, T. P., D'Hondt, R. E., Kulawy, R., Louie, A., & Drusano, G. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05664-11 · Cited by 36
“Although vancomycin is classified as an AUC/MIC ratio-driven antimicrobial, the data that support this were derived from multiple-dailydosing regimens (4, 5, 7, 9, 12, 13, 20, 21).”
MethodDrug Selection and Optimization of Dosage Schedules To Minimize Antimicrobial Resistance
Lees, P., Concordet, D., Aliabadi, F. S., & Toutain, P. (2019) · ASM Press eBooks · doi:10.1128/9781555817534.ch5 · Cited by 36
Zhanel, G. G., Schroeder, C., Vercaigne, L. M., Gin, A. S., Embil, J. M., & Hoban, D. J. (2001) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2001/260651 · Cited by 36
“Subinhibitory drug concentrations and postantimicrobial effects are also important factors when determining dosing schedules (59).”
BackgroundModeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients
Lyons, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02359-17 · Cited by 36
Severe pneumococcal pneumonia: new strategies for management
Chiou, C. C., & Yu, V. L. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.ccx.0000244129.69742.d9 · Cited by 36
Guerrero, M. L. F., Ramos, J. M., Marrero, J. A., Cuenca, M., Roblas, R. F., & Górgolas, M. (2003) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(03)90042-7 · Cited by 36
Noreddin, A. M., Marras, T. K., Sanders, K. M., Chan, C. K., Hoban, D. J., & Zhanel, G. G. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.06.010 · Cited by 36
A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units
Dulhunty, J. M., Webb, S. A. R., Paterson, D. L., Bellomo, R., Myburgh, J., Roberts, J. A., & Lipman, J. (2010) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01499-0 · Cited by 36
Pharmacokinetics of Cefepime in Patients with Thermal Burn Injury
Bonapace, C. R., White, R. L., Friedrich, L. V., Norcross, E. D., & Bosso, J. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2848 · Cited by 36
“Mean (standard deviation [SD]) age, actual body weight (ABW), percent total body surface area burned, and days postburn at the time of study were 41 (13) years, 84 (22) kg, 36 (17)%, and 9 (3) days, respectively.”
BackgroundMethodInfluentialXiao, X., Sun, J. G., Yang, T., Fang, X., Wu, D., Xiong, Y. Q., Cheng, J., Chen, Y., Shi, W., & Liu, Y. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00200-15 · Cited by 36
“The use of a PK-PD model to identify the PD activity by integrating the PK character, MIC, and pathogen load outcome has been proven helpful in the design of rational dosage regimens in humans and animals and in the determination of susceptibility breakpoints (24, 25).”
MethodGranizo, J. J., Giménez, M.-J., Barberdn, J., Coronel, P., Gimeno, M., & Aguilar, L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.12.010 · Cited by 36
Kim, M., Zhou, W., Tessier, P. R., Xuan, D., Ye, M., Nightingale, C. H., & Nicolau, D. P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3185-3192.2002 · Cited by 36
“The thigh infection model is the most commonly used in vivo model for assessment of PD, since this model produces relatively less data variability than other infection models (3, 4).”
MethodIntraabdominal tissue concentration of ertapenem
Wittau, M., Wagner, E., Kaever, V., Koal, T., Henne‐Bruns, D., & Isenmann, R. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki459 · Cited by 36
Nagai, K., Davies, T. A., Dewasse, B. E., Jacobs, M. R., & Appelbaum, P. C. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.365 · Cited by 36
Romano, J., Kashuba, A. D. M., Becker, S. L., Cummins, J. E., Turpin, J. A., & Veronese, O. B. O. T. A. F. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0122 · Cited by 35
Chapagain, M. L., Pasipanodya, J. G., Athale, S., Bernal, C., Trammell, R., Howe, D., & Gumbo, T. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac068 · Cited by 35
Al‐Shaer, M. H., Maranchick, N. F., Bai, C., Maguigan, K. L., Shoulders, B. R., Felton, T., Mathew, S. K., Mardini, M., & Peloquin, C. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-22 · Cited by 35
Use of therapeutic drug monitoring to characterize cefepime‐related neurotoxicity
Venugopalan, V., Casaus, D. V., Kainz, L., Slaton, C. N., Hurst, N., Bruzzone, M., Hu, C., Sword, G., Cherabuddi, K., Iovine, N. M., et al. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2744 · Cited by 35
Chiang, S., Chuang, Y.-C., Tang, H.-J., Chen, C.-C., Chen, C.-H., Lee, N., Chou, C. H., & Ko, W. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181a0f8e1 · Cited by 35
“Finally, pharmacodynamics in mice and humans are different (29); the corresponding human doses should be investigated in clinical trials.”
BackgroundHelmy, S. A. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318297b6b0 · Cited by 35
Bioadhesive Controlled Metronidazole Release Matrix Based on Chitosan and Xanthan Gum
Eftaiha, A. F., Qinna, N. A., Rashid, I., Remawi, M. M. A., Shami, M. R. A., Arafat, T., & Badwan, A. A. (2010) · Marine Drugs · doi:10.3390/md8051716 · Cited by 35
“Thus, in order to increase efficacy, there is a need to increase the total amount of drug given per dose [34].”
BackgroundLandersdorfer, C. B., Bulitta, J. B., Kirkpatrick, C. M. J., Kinzig, M., Holzgrabe, U., Drusano, G. L., Stephan, U., & Sörgel, F. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00937-12 · Cited by 35
“This is the commonly used target for near-maximal bactericidal activity of penicillins at 24 h in murine infection models (2, 3, 16, 17).”
BackgroundAgudelo, M., & Vesga, Ó. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06012-11 · Cited by 35
“Concentration-dependent antibiotics would not behave as expected with very short dosing intervals, and both time- and concentration-dependent drugs would give unreliable results with very long dosing intervals (6, 7).”
BackgroundAntibiotic Dosing in Continuous Renal Replacement Therapy
Shaw, A. R., & Mueller, B. A. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.05.004 · Cited by 35
Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats
Albarellos, G., Montoya, L., & Landoni, M. F. (2004) · The Veterinary Journal · doi:10.1016/j.tvjl.2004.05.011 · Cited by 35
Pharmacokinetic analysis of cefquinome in healthy chickens
Xie, W., Zhang, X., Wang, T.-X., & Du, S. (2013) · British Poultry Science · doi:10.1080/00071668.2013.764399 · Cited by 35
“For many cephalosporins, the time with serum levels above the MIC should be >40% of the dosing interval in order to achieve beneficial therapeutic effects (Craig, 1998).”
BackgroundAntimicrobial resistance among pediatric respiratory tract infections: clinical challenges
Jacobs, M. R., & Dagan, R. (2004) · Seminars in Pediatric Infectious Diseases · doi:10.1053/j.spid.2004.01.003 · Cited by 35
Knudsen, J. D., Odenholt, I., Erlendsdóttir, H., Gottfreðsson, M., Cars, O., Frimodt‐Møller, N., Espersen, F., Kristinsson, K. G., & Gudmundsson, S. R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2499-2506.2003 · Cited by 35
“Therefore, only seldom will the Cmax/MIC ratio be below 10 when the T MIC is above 40%, as widely recommended (5).”
Goessens, W. H. F., Mouton, J. W., ten Kate, M. T., Bijl, A. J., Ott, A., & Bakker‐Woudenberg, I. A. J. M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl529 · Cited by 35
Role of beta-lactam agents in the treatment of community-acquired pneumonia
Garau, J. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-1287-9 · Cited by 35
“Studies using double tympanocentesis in acute otitis media have confirmed this T>MIC range as being effective in eradicating pathogens from the middle ear [48].”
BackgroundInfluentialFormulations of Antibiotics for Children in Primary Care: Effects on Compliance and Efficacy
Ramgoolam, A., & Steele, R. W. (2002) · Pediatric Drugs · doi:10.2165/00128072-200204050-00005 · Cited by 35
Richter, A., Feßler, A. T., Böttner, A., Köper, L. M., Wallmann, J., & Schwarz, Š. (2020) · Veterinary Microbiology · doi:10.1016/j.vetmic.2020.108694 · Cited by 34
Fillâtre, P., Lemaitre, F., Nesseler, N., Schmidt, M., Besset, S., Launey, Y., Maamar, A., Daufresne, P., Flecher, E. M., Tulzo, Y. L., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab031 · Cited by 34
Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review
Castagnola, E., Cangemi, G., Mesini, A., Castellani, C., Martelli, A., Cattaneo, D., & Mattioli, F. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106381 · Cited by 34
Hwang, Y., Song, I.-B., Lee, H. K., Kim, T., Kim, M. S., Lim, J., Park, B. K., & YUN, H. I. (2011) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2011.01289.x · Cited by 34
Slama, T. G. (2008) · Critical Care · doi:10.1186/cc6994 · Cited by 34
“The key pharmacodynamic parameter is the time during which the carbapenem concentration exceeds the minimum inhibitory concentration (T > MIC), which should be at least 20% of the dosing interval for bacteriostatic effect and 40% for maximum killing effect [33,34].”
BackgroundDomínguez-Herrera, J., Velasco, C., Docobo-Pérez, F., Rodríguez-Martínez, J. M., López-Rojas, R., Briales, A., Pichardo, C., Díaz-De-Alba, P., Rodríguez‐Baño, J., Pascual, Á., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt063 · Cited by 34
Hanberg, P., Bue, M., Sørensen, H. B., Søballé, K., & Tøttrup, M. (2015) · The Spine Journal · doi:10.1016/j.spinee.2015.11.031 · Cited by 34
“As mentioned, cefuroxime is a timedependent drug, for which T>MIC has been shown to be the best predictor of efficacy [25].”
BackgroundRumbo, C., Vallejo, J. A., Cabral, M. P., Martínez-Guitián, M., Pérez, A., Beceiro, A., & Bou, G. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw342 · Cited by 34
Nanoantibiotics: A Novel Rational Approach to Antibiotic Resistant Infections
Engin, A. B., & Engin, A. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190806142835 · Cited by 34
Ellison, R. T., & Donowitz, G. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00069-2 · Cited by 34
“β-Lactam compounds are timedependent killers; when a penicillin, cephalosporin, or carbapenem is being used, the active drug levels need to be above the minimal inhibitory concentration (MIC) of the organism being treated for 40% to 50% of the dosing interval for an optimal outcome.(297,298) Parenteral administration…”
Isla, A., Rodríguez‐Gascón, A., Maynar, J., Arzuaga, A., Sánchez-Izquierdo, J. A., & Pedraz, J. L. (2007) · Chemotherapy · doi:10.1159/000100864 · Cited by 34
“Thus keeping plasma of s-lactam antibiotic concentration above MICs for 100p of the dosing interval seems to be justified for an optimal outcome, especially in critically ill patients [ ,”
Background
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.